Article
Impact of low abundance HIV variants on response to ritonavir-boosted atazanavir or fosamprenavir given once daily with tenofovir/emtricitabine in antiretroviral-naive HIV-infected patients.
AIDS research and human retroviruses - 1 Apr 2010
Ross Lisa L, Weinberg Winkler G, DeJesus Edwin, Fischl Margaret A, Horton Joseph H, Pappa Keith A, Lancaster C Tracey, Pakes Gary E, Smith Kimberly Y
Abstract excerpt
Population genotyping (PG) can underestimate resistance if resistance-containing low abundance variants go undetected. PG and clonal analysis (CA) results were compared in virologic failures (VFs) from a 48-week clinical trial that evaluated once-daily fosamprenavir/ritonavir (FPV/r) 1400 mg/100 mg or atazanavir/ritonavir (ATV/r) 300 mg/100 mg, each combined with tenofovir/emtricitabine, in antiretroviral-naive...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.